Author(s): Ghanshyam Sevak, Yashpal Singh Chauhan, Narendra Parihar, Mahendra Singh Rathore

Email(s): yashpalsinghchauhan20@gmail.com

DOI: 10.52711/2321-5836.2022.00018   

Address: Ghanshyam Sevak, Yashpal Singh Chauhan*, Narendra Parihar, Mahendra Singh Rathore
Geetanjali Institute of Pharmacy, Udaipur, Rajasthan., India.
*Corresponding Author

Published In:   Volume - 14,      Issue - 2,     Year - 2022


ABSTRACT:
Novel coronavirus also known as severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) was emerged from Wuhan, China and have taken catastrophic form globally. India being a dense populated country is also affected by it’s deadly infection. Bats were considered as its primary host but COVID-19 disease became pandemic via human to human transmission by droplet nuclei. The incubation period ranges upto 14 days and main symptoms of disease were noticed as atypical pneumonia, fever, difficult breathing, decreased SPO2 level and ultimately death due to respiratory failure depending upon immune status of the patients. Coronaviruses are positive-sense, single-stranded RNA viruses and harbour a genome (30 kb) consisting of two terminal untranslated regions and twelve putative functional open reading frames (ORFs), encoding for non-structural and structural proteins. There are sixteen putative non-structural proteins, including proteases, RNA-dependent RNA polymerase, helicase, other proteins involved in the transcription and replication of SARS-CoV-2, and four structural proteins, including spike protein (S), envelope (E), membrane (M), and nucleocapsid (N). SARS-CoV-2 infection, with a heavy viral load in the body, destroys the human lungs through cytokine storm, especially in elderly persons and people with immunosuppressed disorders. A number of drugs have been repurposed and employed, but still, no specific antiviral medicine has been approved by the FDA to treat this disease. This review provides a current status of the COVID-19, epidemiology, an overview of phylogeny, mode of action, diagnosis, and possible treatment methods and vaccines.


Cite this article:
Ghanshyam Sevak, Yashpal Singh Chauhan, Narendra Parihar, Mahendra Singh Rathore. Review of Novel Corona Virus Disease (Covid-19) in India. Research Journal of Pharmacology and Pharmacodynamics.2022;14(2):99-9. doi: 10.52711/2321-5836.2022.00018

Cite(Electronic):
Ghanshyam Sevak, Yashpal Singh Chauhan, Narendra Parihar, Mahendra Singh Rathore. Review of Novel Corona Virus Disease (Covid-19) in India. Research Journal of Pharmacology and Pharmacodynamics.2022;14(2):99-9. doi: 10.52711/2321-5836.2022.00018   Available on: https://rjppd.org/AbstractView.aspx?PID=2022-14-2-9


REFERENCES:
1.    Andrews MA, Areekal B, Rajesh KR, Krishnan J, Suryakala R, Krishnan B, Muraly CP, Santhosh PV. First confirmed case of COVID-19 infection in India: A case report. The Indian journal of medical research. 2020 May;151(5):490.
2.    Omelicheva MY, Markowitz LP. COVID-19 in Central Asia:(De-) Securitization of a Health Crisis?. Problems of Post-Communism. 2021 Dec 19:1-1.
3.    Belfin RV, Bródka P, Radhakrishnan BL, Rejula V. COVID-19 peak estimation and effect of nationwide lockdown in India. MedRxiv. 2020 Jan 1.
4.    Ananthalakshmi V. The current situation of COVID-19 in India. Brain, Behavior, and Immunity-Health. 2021 Feb 1;11:100200.
5.    Gettleman J, Schultz K. Modi orders 3-week total lockdown for all 1.3 billion Indians. The New York Times. 2020 Mar 24;24:0362-433.
6.    Jeffrey G, Kai S. Modi orders 3-week total lockdown for all 1.3 billion Indians. New York Times Company. 2020 Mar.
7.    Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, Wu J, Luo Z. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Computational and structural biotechnology journal. 2022 Jan 31.
8.    Avillion AE, DEd MS. COVID-19 and Seasonal Flu 2021–2022.
9.    Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. Journal of the Chinese medical association. 2020 Mar;83(3):217.
10.    Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020 Jul 15; 1–5.
11.    Knapp A. The secret history of the first coronavirus. Forbes. Retrieved. 2020 Apr;7(7):2020.
12.    Singh P, Sinha R, Nath SK, Preeti P, Kumari P. COV-DOCK server: A web server for COVID-19 ligand-target docking.
13.    Nuraisyah S, Harahap RD, Harahap DA. Analysis of Internet Media Use of Student Biology Learning Interest During COVID-19. Jurnal Penelitian Pendidikan IPA. 2021 Apr 13;7(2):213-7.
14.    Oster NV, Grace Guenther MP, Frogner BK, Skillman SM. The Clinical Laboratory Workforce in the US.
15.    Raut AP, Huy NT. Political Races, Religious Congregations, and Inefficacious Measures Amid the Second Wave of COVID-19 in India. American journal of public health. 2021 Dec;111(12):2100-2.
16.    Thakur JS, Kaur H. Vaccine distribution for COVID-19 and equity issues in India. International Journal of Noncommunicable Diseases. 2021 Nov 1;6(5):98.
17.    Shukla SC, Pandit S, Soni D, Gogtay NJ. Evaluation of Allergic Reactions following COVID-19 Vaccination in Patients with Documented Allergies. Journal of the Association of Physicians of India. 2021 Oct 1;69(10):11-2.
18.    Callan JP. Estimates of the impact on COVID-19 deaths of unequal global allocations of vaccines. medRxiv. 2022 Jan 1.
19.    Peters MD. Update: COVID-19 vaccine effectiveness, efficacy, and safety.
20.    Patel A, Jernigan DB. Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak—United States, December 31, 2019–February 4, 2020. Morbidity and mortality weekly report. 2020 Feb 7;69(5):140.
21.    Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus pandemic (COVID-19). Our world in data. 2020 Mar 5.
22.    Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. BioRxiv. 2021 Jan 1.
23.    Garcia, Ma. Angelica (August 15, 2021). "First lambda variant case detected in the Philippines". GMA News. Retrieved August 15, 2021.
24.    Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada TA, Kaneda A, Nakagawa S, Sato K. Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. BioRxiv. 2021 Jan 1.
25.    Khan T, Jamal SM. SARS-CoV-2 nomenclature: viruses, variants and vaccines need a standardized naming system. Future virology. 2021 Dec;16(12):777-9.
26.    Zhang L, Zhang B, Lorenzo L, Liberal V. OnSite COVID-19 Ag Rapid Tests Detects Newly Identified SARS-CoV-2 Variants.
27.    Lu L, Mok BW, Chen L, Chan JM, Tsang OT, Lam BH, Chuang VW, Chu AW, Chan WM, Ip JD, Chan BP. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. medRxiv. 2021 Jan 1.
28.    Brief TA. Emergence of SARS-CoV-2 B. 1.617 Variants in India and Situation in the EU/EEA.
29.    Kustwar RK, Ray S. Journal of Multidisciplinary Research in Healthcare.
30.    Niederman MS, Zumla A. Coronavirus disease 2019 (COVID-19)–advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges. Current Opinion in Pulmonary Medicine. 2021 May 1;27(3):141-5.
31.    Kute VB, Guleria S, Bhalla AK, Sharma A, Agarwal SK, Sahay M, Varughese S, Prasad N, Varma PP, Shroff S, Vardhan H. ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19. Indian Journal of Transplantation. 2021 Apr 1;15(2):131.
32.    Lu L, Mok B, Chen L, Chan J, Tsang O, Lam B, Chuang V, Chu A, Chan A, Ip J, Chan B. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.
33.    Bunce M. Rapid-Review: the role COVID-19 genomics can play in contact tracing, cluster analysis and viral evolution.
34.    Assessment RR. Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA–first update. European Centre for Disease Prevention and Control An agency of the European Union. 2021 Jan 2
35.    https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/coronavirus-amid-rising-omicron-cases-here-are-the-drugs-and-treatments-available-for-covid-19-patients/photostory/88757774.cms Coronavirus: Amid rising Omicron cases, here are the drugs and treatments available for COVID-19 patients.
36.    Atal S, Fatima Z, Balakrishnan S. Approval of itolizumab for COVID-19: a premature decision or need of the hour?. BioDrugs. 2020 Dec;34(6):705-11.

Recomonded Articles:

Author(s): Syed Sagheer Ahmed, Chandra Prakash. K, Saba Tabassum, Noor Salma, Ahalya Devi. K H

DOI: 10.5958/2321-5836.2019.00003.X         Access: Open Access Read More

Author(s): Shameer Pasha, Mohamed Khaleel, Sukhen Som.

DOI: Not Available         Access: Open Access Read More

Author(s): Chunendra Kumar, Shiv Shankar Shukla, Ravindra Kumar Pandey

DOI: 10.5958/2321-5836.2017.00016.7         Access: Open Access Read More

Author(s): Purnendu Panda, Banamali Das, DS Sahu, SK Meher, BK Das, MM Rao, GChD Naga Lakshmi.

DOI: 10.5958/2321-5836.2015.00011.7         Access: Open Access Read More

Author(s): Shilpa Maria, IJ Kuppast, JH Virupaksha, M Vanajakshi, K Prasad.

DOI: 10.5958/2321-5836.2015.00033.6         Access: Open Access Read More

Author(s): Purnendu Panda, Banamali Das, DS Sahu, SK Meher, Das, GC Nanda.

DOI: Not Available         Access: Open Access Read More

Author(s): Syed Shafeeq. R, Shekshavali. T, Syed Sulthan Ahamed. S N

DOI: 10.5958/2321-5836.2018.00026.5         Access: Open Access Read More

Author(s): Nikhil P. Varghese, Shekshavali T. , Prathib B., I.J. Kuppast

DOI: 10.5958/2321-5836.2017.00007.6         Access: Open Access Read More

Author(s): Sudhanshu Kumar Meher, Banmali Das, Purnendu Panda, GC Bhuyan, MM Rao.

DOI: 10.5958/2321-5836.2016.00006.9         Access: Open Access Read More

Author(s): Dipti Phadtare, Rajashri Kulkarni

DOI: 10.5958/2321-5836.2016.00016.1         Access: Open Access Read More

Author(s): U. S. Jijith , C. R. Sudhakaran Nair, K. Pramod

DOI: 10.5958/2321-5836.2016.00001.X         Access: Open Access Read More

Author(s): Srinibash Sahoo, AK Das, Kamadev Das.

DOI: 10.5958/2321-5836.2015.00039.7         Access: Open Access Read More

Author(s): Srinibash Sahoo, BCS Rao, AK Das, Kamadev Das.

DOI: Not Available         Access: Open Access Read More

Author(s): Sanjib Kumar Das, Anuradha Das, Banamali Das, Purnendu Panda, G. C. Bhuyan, Bipin Bihari Khuntia

DOI: 10.5958/2321-5836.2017.00036.2         Access: Open Access Read More

Author(s): Sudhanshu Kumar Meher, Purnendu Panda, Banmali Das, G. C. Bhuyan, Dr. K. K. Rath

DOI: 10.5958/2321-5836.2018.00023.X         Access: Open Access Read More

Author(s): Indrayani D. Raut, Akshada N. Kakade , Jadhav Snehal, Jadhav Priyanka, Kabir Amruta

DOI: 10.5958/2321-5836.2017.00002.7         Access: Open Access Read More

Author(s): Satish Narra, Bandenawaz Ramadurg, Saraswathi C D.

DOI: Not Available         Access: Open Access Read More

Author(s): Ajay Kumar Meena, Himanshu Sehgal, MM Rao, P Panda, MM Padhi.

DOI: Not Available         Access: Open Access Read More

Research Journal of Pharmacology and Pharmacodynamics (RJPPD) is an international, peer-reviewed journal....... Read more >>>

RNI: Not Available                     
DOI: 10.5958 2321-5836 


Recent Articles




Tags